Announcements

  • All
  • Announcements 2009
  • Announcements 2010
  • Announcements 2011
  • Announcements 2012
  • Announcements 2017
  • Announcements 2018
  • Announcements 2019
  • Announcements 2020
  • Announcements 2021
  • Announcements 2022
  • Announcements 2024
  • Announcements 2026

Flash Note: Annual Financial Results 2025 (Unaudited Financial Data) Strong EBITDA Growth of 48.9% and Significant Increase in Earnings Before Tax by 108,2% Paiania, March 19, 2026 - Lavipharm S.A. informs the investment community of the key financial figures for fiscal year 2025. Consolidated Sales from...

Paiania, 05 March 2026 - Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2026, as follows.. FINANCIAL CALENDAR 2026...

Peania, November 17, 2025 – Lavipharm S.A. informs the investment community of the Group’s key consolidated financial figures for the nine-month period of 2025. Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) from continuing and discontinued operations increased by 11.2%, reaching €10.47 million compared...

Financial Results for the First Half of 2025 – Steady Growth Momentum Peania, September 18, 2025 – Lavipharm Group reports an increase in its consolidated sales during the First Half of 2025. Specifically, consolidated sales from continuing operations amounted to €31.0 million, compared to €29.3 million...

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) Increased by 32.4% Paiania, 15 May 2025 – Lavipharm Group’s total earnings before interest, taxes, depreciation, and amortization (EBITDA) for the First Quarter of 2025 increased by 32.4%, amounting to EUR 3.77 million compared to EUR 2.85 million...

(Unaudited Financial Data) Significant Sales and EBITDA Growth – Strong increase in net profit   Paiania, 19 March 2025 - Lavipharm S.A. informs the investment community on the key financial figures for the fiscal year 2024, as well as the Group’s operational developments to date: Consolidated Sales from ongoing...

Paiania, 14 March 2025 – Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2025, as follows:   Wednesday, 19 March 2025 Flash Note on Financial Results of FY 2024 Thursday, 3 April 2025 Announcement of FY 2024 Financial Report Thursday, 24...

Paiania, 4 February 2025 – Lavipharm S.A., a Pharmaceutical, Chemical, and Cosmetic Products Commercial and Industrial Societe Anonyme (hereinafter the “Company”), announces, in accordance with the provisions of Article 19 of Regulation (EU) No. 596/2014 and following a relevant notification received, that on 3 February...

Peania, 23 January 2025 – Lavipharm announces a strategic commercial agreement with the multinational company iNova Pharmaceuticals, the owner of Betadine® and other trusted brands. The new partnership involves the licensing rights of a new antiseptic pharmaceutical OTC product developed by Lavipharm to be commercialized by...